315 related articles for article (PubMed ID: 30060910)
1. Pasireotide is not effective in reducing the development of postoperative pancreatic fistula.
Young S; Sung ML; Lee JA; DiFronzo LA; O'Connor VV
HPB (Oxford); 2018 Sep; 20(9):834-840. PubMed ID: 30060910
[TBL] [Abstract][Full Text] [Related]
2. Risk-stratified analysis of pasireotide for patients undergoing pancreatectomy.
Peng JS; Joyce D; Brady M; Groman A; Attwood K; Kuvshinoff B; Hochwald SN; Kukar M
J Surg Oncol; 2020 Aug; 122(2):195-203. PubMed ID: 32474957
[TBL] [Abstract][Full Text] [Related]
3. Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis.
Denbo JW; Slack RS; Bruno M; Cloyd JM; Prakash L; Fleming JB; Kim MP; Aloia TA; Vauthey JN; Lee JE; Katz MH
J Gastrointest Surg; 2017 Apr; 21(4):636-646. PubMed ID: 28050766
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
Dalton EC; Johns MS; Rhodes L; Merritt WT; Petrelli NJ; Tiesi GG
Am Surg; 2020 May; 86(5):429-436. PubMed ID: 32684027
[TBL] [Abstract][Full Text] [Related]
5. Meta-Analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
Dalton EC; Johns MS; Rhodes L; Merritt WT; Petrelli NJ; Tiesi GJ
Am Surg; 2020 Dec; 86(12):1728-1735. PubMed ID: 32870029
[TBL] [Abstract][Full Text] [Related]
6. The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial.
Ma LW; Dominguez-Rosado I; Gennarelli RL; Bach PB; Gonen M; D'Angelica MI; DeMatteo RP; Kingham TP; Brennan MF; Jarnagin WR; Allen PJ
Ann Surg; 2017 Jan; 265(1):11-16. PubMed ID: 27429029
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Pasireotide for Prevention of Postoperative Pancreatic Fistula in Pancreatic Surgery: a Systematic Review and Meta-analysis.
Liu X; Pausch T; Probst P; Cui J; Wei J; Hackert T; Miao Y
J Gastrointest Surg; 2020 Jun; 24(6):1421-1429. PubMed ID: 32207077
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for postoperative pancreatic fistula in the Era of pasireotide.
Potter KC; Sutton TL; O'Grady J; Gilbert EW; Pommier R; Mayo SC; Sheppard BC
Am J Surg; 2022 Aug; 224(2):733-736. PubMed ID: 35221100
[TBL] [Abstract][Full Text] [Related]
9. Pasireotide does not prevent postoperative pancreatic fistula: a prospective study.
Elliott IA; Dann AM; Ghukasyan R; Damato L; Girgis MD; King JC; Hines OJ; Reber HA; Donahue TR
HPB (Oxford); 2018 May; 20(5):418-422. PubMed ID: 29398424
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide administration after pancreaticoduodenectomy may decrease clinically relevant postoperative pancreatic fistula in high-risk patients with small pancreatic ducts, soft pancreatic parenchyma and cystic or neuroendocrine neoplasia.
Vuorela T; Mustonen H; Kokkola A; Haglund C; Seppänen H
Pancreatology; 2020 Jun; 20(4):757-761. PubMed ID: 32307251
[TBL] [Abstract][Full Text] [Related]
11. Impact of pasireotide on postoperative pancreatic fistulas following distal resections.
Vuorela T; Mustonen H; Kokkola A; Haglund C; Seppanen H
Langenbecks Arch Surg; 2021 May; 406(3):735-742. PubMed ID: 33474568
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after Pancreatectomy with Routine Pasireotide Use.
Kunstman JW; Goldman DA; Gönen M; Balachandran VP; D'Angelica MI; Kingham TP; Jarnagin WR; Allen PJ
J Am Coll Surg; 2019 Feb; 228(2):161-170.e2. PubMed ID: 30414453
[TBL] [Abstract][Full Text] [Related]
13. Prospective Evaluation of Pasireotide in Patients Undergoing Pancreaticoduodenectomy: The Washington University Experience.
Dominguez-Rosado I; Fields RC; Woolsey CA; Williams G; Horwedel TA; Rose JB; Hammill CW; Doyle MB; Chapman WC; Strasberg SM; Hawkins WG; Sanford DE
J Am Coll Surg; 2018 Feb; 226(2):147-154.e1. PubMed ID: 29133263
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness comparison of prophylactic octreotide and pasireotide for prevention of fistula after pancreatic surgery.
Welsch T; Müssle B; Distler M; Knoth H; Weitz J; Häckl D
Langenbecks Arch Surg; 2016 Nov; 401(7):1027-1035. PubMed ID: 27233242
[TBL] [Abstract][Full Text] [Related]
15. Do somatostatin-analogues have the same impact on postoperative morbidity and pancreatic fistula in patients after pancreaticoduodenectomy and distal pancreatectomy? - A systematic review with meta-analysis of randomized-controlled trials.
Schorn S; Vogel T; Demir IE; Demir E; Safak O; Friess H; Ceyhan GO
Pancreatology; 2020 Dec; 20(8):1770-1778. PubMed ID: 33121847
[TBL] [Abstract][Full Text] [Related]
16. Pasireotide for postoperative pancreatic fistula.
Allen PJ; Gönen M; Brennan MF; Bucknor AA; Robinson LM; Pappas MM; Carlucci KE; D'Angelica MI; DeMatteo RP; Kingham TP; Fong Y; Jarnagin WR
N Engl J Med; 2014 May; 370(21):2014-22. PubMed ID: 24849084
[TBL] [Abstract][Full Text] [Related]
17. Effect of Hydrocortisone vs Pasireotide on Pancreatic Surgery Complications in Patients With High Risk of Pancreatic Fistula: A Randomized Clinical Trial.
Tarvainen T; Sirén J; Kokkola A; Sallinen V
JAMA Surg; 2020 Apr; 155(4):291-298. PubMed ID: 32022887
[TBL] [Abstract][Full Text] [Related]
18. Excess Weight Adversely Influences Treatment Length of Postoperative Pancreatic Fistula: A Retrospective Study of 900 Patients.
Fujii T; Kanda M; Nagai S; Suenaga M; Takami H; Yamada S; Sugimoto H; Nomoto S; Nakao A; Kodera Y
Pancreas; 2015 Aug; 44(6):971-6. PubMed ID: 25906445
[TBL] [Abstract][Full Text] [Related]
19. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis.
Goyert N; Eeson G; Kagedan DJ; Behman R; Lemke M; Hallet J; Mittmann N; Law C; Karanicolas PJ; Coburn NG
Ann Surg; 2017 Jan; 265(1):2-10. PubMed ID: 27537539
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and meta-analysis of prophylactic abdominal drainage after pancreatic resection.
Dou CW; Liu ZK; Jia YL; Zheng X; Tu KS; Yao YM; Liu QG
World J Gastroenterol; 2015 May; 21(18):5719-34. PubMed ID: 25987799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
